Skip to main content
IOVAIovance Biotherapeutics, Inc.Sell6.0·$7.99

Iovance Biotherapeutics (IOVA) Q3 2026 earnings — TrendMatrix coverage

BEAT · SMALLER LOSS+41.4% vs estimateEPS -$0.05 vs -$0.09 estCurrent verdict Sell 6.0/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
-$0.05
Estimate
-$0.09
Surprise
+41.4%
Revenue (period 2026-09-30)
$121.5M
Score today
6.0/10

Revenue source: xbrl.

Report record · Q3 2026

How the report landed

Iovance Biotherapeutics (IOVA) reported a narrower loss than forecast — adjusted EPS of -$0.05 against the -$0.09 estimate (a 41.4% beat on a still-unprofitable quarter).

Around the report

Coverage in the report window

  • Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19 — benzinga, 2026-11-06
  • Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $12 — benzinga, 2026-11-06
  • Iovance Biotherapeutics Q3 2026 Earnings Call Transcript — benzinga, 2026-11-05
Current read · as of 2026-11-06

Where TrendMatrix's rating stands now

TrendMatrix currently rates IOVA Sell at 6.0/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +41.4% surprise compares with a +8.5% four-quarter average.

What argues against it

  • Concentration risk — Pipeline: TILVANCE-301 (Amtagvi confirmatory Phase 3)
  • Quality below floor (3.1 < 4.0)
  • Momentum score 2.7/10 — below 4.5 minimum

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$7.99
Price target
$12.44
Stop
$7.43
Upside to target
+55.8%
Reward-to-risk
3.7:1

Risk check: RSI 23 — a level conventionally read as oversold.

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare context

IOVA at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$3.51B
P/E (fwd)
-39.5
52-week range
$2.08–$15.37
Off 52-week high
48.0%
RSI (14)
23
Volume vs avg
0.30×
Score today
6.0/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › IOVA › Earnings › Q3 2026 earnings